Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma

NCT06463522 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT06463522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06463522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma
Lead sponsor
Beijing 302 Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2024
Completion date
July 1, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma